{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:24:04Z","timestamp":1763043844554,"version":"3.45.0"},"reference-count":49,"publisher":"Informa UK Limited","issue":"17","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Janssen Scientific Affairs, LLC, a Johnson & Johnson company"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,7,15]]},"DOI":"10.1080\/14796694.2025.2514399","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T11:21:10Z","timestamp":1749122470000},"page":"2155-2165","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Burden of illness among patients with relapsed or refractory multiple myeloma, and eligible for B-cell maturation antigen-targeted therapies"],"prefix":"10.1080","volume":"21","author":[{"given":"Smith","family":"Giri","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham","place":["Birmingham, USA"]},{"name":"University of Alabama at Birmingham","place":["Birmingham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dee","family":"Lin","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth Wangia","family":"Dixon","sequence":"additional","affiliation":[{"name":"Carelon Research","place":["Wilmington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Kim","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Fowler","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Barron","sequence":"additional","affiliation":[{"name":"Carelon Research","place":["Wilmington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiangkiat","family":"Tan","sequence":"additional","affiliation":[{"name":"Carelon Research","place":["Wilmington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Carelon Research","place":["Wilmington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feven","family":"Asefaha","sequence":"additional","affiliation":[{"name":"Carelon Research","place":["Wilmington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiva","family":"Vojjala","sequence":"additional","affiliation":[{"name":"Carelon Research","place":["Wilmington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elissa E.","family":"Min","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, USA"]},{"name":"College of Pharmacy, Purdue University","place":["West Lafayette, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingcao","family":"Wu","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"e_1_3_7_3_1","unstructured":"National Cancer Institute. SEER cancer stat facts: myeloma. Bethesda (MD USA): National Cancer Institute; 2023 [cited 2024 Mar 8]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_3_7_4_1","unstructured":"Leukemia & Lymphoma Society. Facts and statistics overview: general blood cancers. 2023 [cited 2024 Mar 8]. Available from: https:\/\/www.lls.org\/facts-and-statistics\/facts-and-statistics-overview#:~:text=General%20Blood%20Cancers -New%20Cases&text=Approximately%20every%203%20minutes%2C%20one lymphoma%20or%20myeloma%20in%202023"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0057"},{"key":"e_1_3_7_6_1","unstructured":"American Cancer Society. Cancer facts & figures 2021. 2021 [cited 2024 Mar 7]. Available from: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2021\/cancer-facts-and-figures-2021.pdf"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.03.019"},{"issue":"2","key":"e_1_3_7_8_1","first-page":"e528","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos MA","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021 Feb;5(2):e528.","journal-title":"Hemasphere"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0002"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0689-1"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6619"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020265"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0061"},{"key":"e_1_3_7_14_1","unstructured":"Bristol Myers Squibb. ABECMA (idecabtagene vicleucel) prescribing information. Summit (NJ): Celgene Corporation; 2021 [updated 2021 Mar; cited 2024 Mar 8]. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_abecma.pdf"},{"key":"e_1_3_7_15_1","unstructured":"GSK. GSK provides an update on blenrep (belantamab mafodotin-blmf) US marketing authorisation. London (UK): GSK; 2022 [updated 2022 Nov; cited 2024 Mar 8]. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-blenrep-us-marketing-authorisation\/"},{"key":"e_1_3_7_16_1","unstructured":"Janssen Biotech. CARVYKTI (ciltacabtagene autoleucel) prescribing information horsham. (PA): Janssen Biotech Inc; 2022 [updated 2023 Dec; cited 2024 Mar 8]. Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CARVYKTI-pi.pdf"},{"key":"e_1_3_7_17_1","unstructured":"Janssen Biotech. TECVAYLI (teclistamab-cqyv) prescribing information horsham. (PA): Janssen Pharmaceutical Companies; 2022 [updated 2024 Feb; cited 2024 Mar 8]. Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TECVAYLI-pi.pdf"},{"key":"e_1_3_7_18_1","unstructured":"Pfizer Labs. ELREXFIO (elranatamab-bcmm) prescribing information. New York (NY): Pfizer Laboratories; 2023 [updated 2023 Aug; cited 2024 Mar 8]. Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19669"},{"key":"e_1_3_7_19_1","unstructured":"Janssen Biotech. TALVEY (talquetamab-tgvs) prescribing information horsham PA: Janssen Pharmaceutical Companies. 2023 [updated 2023 Aug; cited 2024 Apr 3]. Available from:https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TALVEY-pi.pdf"},{"key":"e_1_3_7_20_1","unstructured":"U.S. Food and Drug Administration. 2024 biological license application supplement noteworthy approvals. 2024 [updated 2024 Sept 19; cited 2024 Sep 24]. Available from: https:\/\/news.bms.com\/news\/details\/2024\/U.S.-FDA-Approves-Bristol-Myers-Squibb-and-2seventy-bios-Abecma-for-Triple-Class-Exposed-Relapsed-or-Refractory-Multiple-Myeloma-After-Two-Prior-Lines-of-Therapy\/default.aspx#:~:text=Abecma%20was%20recently%20approved%20in more%20prior%20lines%20of%20therapy"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70110"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.1754"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/POR.S140579"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.1772"},{"key":"e_1_3_7_25_1","unstructured":"U.S. Census Bureau. 2013\u20142017 American community survey 5-year data profile. [cited 2022 Oct 28]. Available from: https:\/\/www.census.gov\/acs\/www\/data\/data-tables-and-tools\/data-profiles\/2017\/"},{"key":"e_1_3_7_26_1","unstructured":"Bonito AJ Bann C Eicheldinger C et al. Creation of new race-ethnicity codes and socioeconomic status (SES) indicators for Medicare beneficiaries. Final report sub-task 2. (prepared by RTI International for the centers for Medicare and Medicaid services through an interagency agreement with the agency for healthcare research and policy under contract No. 500\u201300\u20130024 task No. 21). AHRQ publication No. 08\u20130029-EF. Rockville MD2008."},{"key":"e_1_3_7_27_1","unstructured":"Carelon Research. Carelon research\u2019s healthcare integrated research database: technical White paper. Wilmington DE2024. p. 12."},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5518"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"e_1_3_7_30_1","unstructured":"Healthcare Cost and Utilization Project (HCUP). Agency for healthcare research and Quality (US). Clinical classifications software refined (CCSR) for ICD-10-CM diagnoses. [cited 2022 Apr 25]. Available from: https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/ccsr\/dxccsr.jsp"},{"key":"e_1_3_7_31_1","unstructured":"Healthcare Cost and Utilization Project (HCUP). Agency for healthcare research and Quality (US). Clinical classifications software (CCS) for ICD-10-PCS (beta version). [cited 2022 Apr 25]. Available from: https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/ccs10\/ccs10.jsp"},{"key":"e_1_3_7_32_1","unstructured":"U.S. Bureau of Labor Statistics. Consumer price index. 2022 [cited 2022 Apr 25]. Available from: https:\/\/www.bls.gov\/cpi\/home.htm"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2018.100215"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep16010009"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.012674"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13597"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-1003"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1018"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13976"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.136"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159707"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1648802"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.8.917"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00431-5"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2514399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:19:37Z","timestamp":1763043577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2514399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":49,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,7,15]]}},"alternative-id":["10.1080\/14796694.2025.2514399"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2514399","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}